It's all about the perspective: Removing bias when co-managing patients with high-grade T1 bladder cancer and localized prostate cancer-A competing risks analysis

J E Ferguson 3rd; Ashish M Kamat

doi:10.1016/j.urolonc.2017.10.019

It's all about the perspective: Removing bias when co-managing patients with high-grade T1 bladder cancer and localized prostate cancer-A competing risks analysis

Urol Oncol. 2018 Feb;36(2):39-42. doi: 10.1016/j.urolonc.2017.10.019. Epub 2017 Nov 20.

Authors

J E Ferguson 3rd¹, Ashish M Kamat²

Affiliations

¹ Department of Urology, MD Anderson Cancer Center, Houston, TX.
² Department of Urology, MD Anderson Cancer Center, Houston, TX. Electronic address: akamat@mdanderson.org.

PMID: 29158136
DOI: 10.1016/j.urolonc.2017.10.019

Abstract

The risk connotation of terminology in influencing decision-making should not be underestimated. For example, "superficial" T1HG bladder cancer has the same poor cancer-specific survival as that conferred by the "highest risk" prostate cancer (Gleason 10, T3b). Co-management of concomitant prostate cancer and non-muscle invasive bladder cancer requires a careful competing risk analysis by both the physician and patient. Herein, we detail how patients and physicians should be careful not to underestimate the risk attributed to "non-muscle invasive" bladder cancer.

Keywords: Bladder cancer; Prostate cancer.

Publication types

Case Reports

MeSH terms

Adenocarcinoma / diagnosis*
Carcinoma, Transitional Cell / pathology
Carcinoma, Transitional Cell / surgery*
Humans
Male
Middle Aged
Prostatic Neoplasms / diagnosis*
Risk Factors
Urinary Bladder Neoplasms / pathology
Urinary Bladder Neoplasms / surgery*